Sickness behavior

Last updated
Ancher, Michael, "The Sick Girl", 1882, Statens Museum for Kunst Michael Ancher 001.jpg
Ancher, Michael, "The Sick Girl", 1882, Statens Museum for Kunst

Sickness behavior is a coordinated set of adaptive behavioral changes that develop in ill individuals during the course of an infection. [1] They usually, but not always, [2] accompany fever and aid survival. Such illness responses include lethargy, depression, anxiety, malaise, loss of appetite, [3] [4] sleepiness, [5] hyperalgesia, [6] reduction in grooming [1] [7] and failure to concentrate. [8] Sickness behavior is a motivational state that reorganizes the organism's priorities to cope with infectious pathogens. [8] [9] It has been suggested as relevant to understanding depression, [10] and some aspects of the suffering that occurs in cancer.

Contents

History

Sick animals have long been recognized by farmers as having different behavior. Initially it was thought that this was due to physical weakness that resulted from diverting energy to the body processes needed to fight infection. However, in the 1960s, it was shown that animals produced a blood-carried factor X that acted upon the brain to cause sickness behavior. [11] [12] In 1987, Benjamin L. Hart brought together a variety of research findings that argued for them being survival adaptations that if prevented would disadvantage an animal's ability to fight infection. In the 1980s, the blood-borne factor was shown to be proinflammatory cytokines produced by activated leukocytes in the immune system in response to lipopolysaccharides (a cell wall component of Gram-negative bacteria). These cytokines acted by various humoral and nerve routes upon the hypothalamus and other areas of the brain. Further research showed that the brain can also learn to control the various components of sickness behavior independently of immune activation.[ citation needed ].

In 2015, Shakhar and Shakhar [13] suggested instead that sickness behavior developed primarily because it protected the kin of infected animals from transmissible diseases. According to this theory, termed the Eyam hypothesis, after the English Parish of Eyam, sickness behavior protects the social group of infected individuals by limiting their direct contacts, preventing them from contaminating the environment, and broadcasting their health status. Kin selection would help promote such behaviors through evolution. In a highly prosocial species like humans, however, sickness behavior may act as a signal to motivate others to help and care for the sick individual. [14]

Advantages

General advantage

Sickness behavior in its different aspects causes an animal to limit its movement; the metabolic energy not expended in activity is diverted to the fever responses, which involves raising body temperature. [1] This also limits an animal's exposure to predators while it is cognitively and physically impaired. [1]

Specific advantages

The individual components of sickness behavior have specific individual advantages. Anorexia limits food ingestion and therefore reduces the availability of iron in the gut (and from gut absorption). Iron may aid bacterial reproduction, so its reduction is useful during sickness. [15] Plasma concentrations of iron are lowered for this anti-bacterial reason in fever. [16] Lowered threshold for pain ensures that an animal is attentive that it does not place pressure on injured and inflamed tissues that might disrupt their healing. [1] Reduced grooming is adaptive since it reduces water loss. [1]

Inclusive fitness advantages

According to the 'Eyam hypothesis', [13] sickness behavior, by promoting immobility and social disinterest, limits the direct contacts of individuals with their relatives. By reducing eating and drinking, it limits diarrhea and defecation, reducing environmental contamination. By reducing self-grooming and changing stance, gait and vocalization, it also signals poor health to kin. All in all, sickness behavior reduces the rate of further infection, a trait that is likely propagated by kin selection.[ citation needed ]

Social advantage

Humans helped each other in case of sickness or injury throughout their hunter-gatherer past and afterwards. Convincing others of being badly in need of relief, assistance, and care heightened the chance of survival of the sick individual. High direct costs, such as energy spent on fever and potential harm caused by high body temperatures, and high opportunity costs, as caused by inactivity, social disinterest, and lack of appetite, make sickness behavior a highly costly and therefore credible signal of need. [14]

Immune control

Lipopolysaccharides trigger the immune system to produce proinflammatory cytokines IL-1, IL-6, and tumor necrosis factor (TNF). [17] These peripherally released cytokines act on the brain via a fast transmission pathway involving primary input through the vagus nerves, [18] [19] and a slow transmission pathway involving cytokines originating from the choroid plexus and circumventricular organs and diffusing into the brain parenchyma by volume transmission. [20] Peripheral cytokines are capable of entering the brain directly [21] [22] but are large lipophilic polypeptide proteins that generally do not easily passively diffuse across the blood-brain barrier. They may also induce the expression of other cytokines in the brain that cause sickness behavior. [23] [24] Acute psychosocial stress enhances the ability of an immune response to trigger both inflammation and behavioral sickness. [25]

Behavioral conditioning

The components of sickness behavior can be learned by conditional association. For example, if a saccharin solution is given with a chemical that triggers a particular aspect of sickness behavior, on later occasions the saccharin solution will trigger it by itself. [26] [27]

Medical conditions

Depression

It has been proposed that major depressive disorder is nearly identical with sickness behavior, raising the possibility that it is a maladaptive manifestation of sickness behavior due to abnormalities in circulating cytokines. [28] [29] [30] Moreover, chronic, but not acute, treatment with antidepressant drugs was found to attenuate sickness behavior symptoms in rodents. [31] The mood effects caused by interleukin-6 following an immune response have been linked to increased activity within the subgenual anterior cingulate cortex, [32] an area involved in the etiology of depression. [33] Inflammation-associated mood change can also produce a reduction in the functional connectivity of this part of the brain to the amygdala, medial prefrontal cortex, nucleus accumbens, and superior temporal sulcus. [32]

Cancer side effect

In cancer, both the disease and the chemotherapy treatment can cause proinflammatory cytokine release which can cause sickness behavior as a side effect. [34] [35]

See also

Related Research Articles

<span class="mw-page-title-main">Tumor necrosis factor</span> Protein

Tumor necrosis factor is a cytokine and member of the TNF superfamily, which consists of various transmembrane proteins with a homologous TNF domain. It is the first cytokine to be described as an adipokine as secreted by adipose tissue.

<span class="mw-page-title-main">Lipopolysaccharide</span> Class of molecules found in the outer membrane of Gram-negative bacteria

Lipopolysaccharide, now more commonly known as Endotoxin, is a collective term for components of the outermost membrane of cell envelope of Gram-negative bacteria, such as E. coli and Salmonella. with a common structural architecture. Lipopolysaccharides (LPS) are large molecules consisting of 3 parts: an outer core polysaccharide termed the O-antigen, an inner core oligosaccharide and Lipid A, all covalently linked. In current terminology, the term endotoxin is often used synonymously with LPS, although there are a few endotoxins that are not related to LPS, such as the so-called delta endotoxin proteins produced by Bacillus thuringiensis.

Somnolence is a state of strong desire for sleep, or sleeping for unusually long periods. It has distinct meanings and causes. It can refer to the usual state preceding falling asleep, the condition of being in a drowsy state due to circadian rhythm disorders, or a symptom of other health problems. It can be accompanied by lethargy, weakness and lack of mental agility.

Psychoneuroimmunology (PNI), also referred to as psychoendoneuroimmunology (PENI) or psychoneuroendocrinoimmunology (PNEI), is the study of the interaction between psychological processes and the nervous and immune systems of the human body. It is a subfield of psychosomatic medicine. PNI takes an interdisciplinary approach, incorporating psychology, neuroscience, immunology, physiology, genetics, pharmacology, molecular biology, psychiatry, behavioral medicine, infectious diseases, endocrinology, and rheumatology.

<span class="mw-page-title-main">Hyperalgesia</span> Abnormally increased sensitivity to pain

Hyperalgesia is an abnormally increased sensitivity to pain, which may be caused by damage to nociceptors or peripheral nerves and can cause hypersensitivity to stimulus. Prostaglandins E and F are largely responsible for sensitizing the nociceptors. Temporary increased sensitivity to pain also occurs as part of sickness behavior, the evolved response to infection.

<span class="mw-page-title-main">Interleukin 10</span> Anti-inflammatory cytokine

Interleukin 10 (IL-10), also known as human cytokine synthesis inhibitory factor (CSIF), is an anti-inflammatory cytokine. In humans, interleukin 10 is encoded by the IL10 gene. IL-10 signals through a receptor complex consisting of two IL-10 receptor-1 and two IL-10 receptor-2 proteins. Consequently, the functional receptor consists of four IL-10 receptor molecules. IL-10 binding induces STAT3 signalling via the phosphorylation of the cytoplasmic tails of IL-10 receptor 1 + IL-10 receptor 2 by JAK1 and Tyk2 respectively.

<span class="mw-page-title-main">Interleukin 6</span> Cytokine protein

Interleukin 6 (IL-6) is an interleukin that acts as both a pro-inflammatory cytokine and an anti-inflammatory myokine. In humans, it is encoded by the IL6 gene.

<span class="mw-page-title-main">Interleukin 18</span> Protein-coding gene in the species Homo sapiens

Interleukin-18 (IL-18), also known as interferon-gamma inducing factor is a protein which in humans is encoded by the IL18 gene. The protein encoded by this gene is a proinflammatory cytokine. Many cell types, both hematopoietic cells and non-hematopoietic cells, have the potential to produce IL-18. It was first described in 1989 as a factor that induced interferon-γ (IFN-γ) production in mouse spleen cells. Originally, IL-18 production was recognized in Kupffer cells, and liver-resident macrophages. However, IL-18 is constitutively expressed in non-hematopoietic cells, such as intestinal epithelial cells, keratinocytes, and endothelial cells. IL-18 can modulate both innate and adaptive immunity and its dysregulation can cause autoimmune or inflammatory diseases.

<span class="mw-page-title-main">Interleukin 32</span> Protein-coding gene in the species Homo sapiens

Interleukin 32 (IL32) is proinflammatory cytokine that in humans is encoded by the IL32 gene. Interleukin 32 can be found in higher mammals but not in rodents. It is mainly expressed intracellularly and the protein has nine different isoforms, because the pre-mRNA can be alternatively spliced. The most active and studied isoform is IL-32γ. It was first reported in 2005, although the IL-32 gene was first described in 1992. It does not belong to any cytokine family because there is almost no homology with other cytokines.

<span class="mw-page-title-main">Interleukin 25</span> Cytokine that belongs to the IL-17 cytokine family

Interleukin-25 (IL-25) – also known as interleukin-17E (IL-17E) – is a protein that in humans is encoded by the IL25 gene on chromosome 14. IL-25 was discovered in 2001 and is made up of 177 amino acids.

<span class="mw-page-title-main">Toll-like receptor 4</span> Cell surface receptor found in humans

Toll-like receptor 4 (TLR4), also designated as CD284, is a key activator of the innate immune response and plays a central role in the fight against bacterial infections. TLR4 is a transmembrane protein of approximately 95 kDa that is encoded by the TLR4 gene.

The cholinergic anti-inflammatory pathway regulates the innate immune response to injury, pathogens, and tissue ischemia. It is the efferent, or motor arm of the inflammatory reflex, the neural circuit that responds to and regulates the inflammatory response.

<span class="mw-page-title-main">Interleukin-17A</span> Protein-coding gene in the species Homo sapiens

Interleukin-17A is a protein that in humans is encoded by the IL17A gene. In rodents, IL-17A used to be referred to as CTLA8, after the similarity with a viral gene.

<span class="mw-page-title-main">Interleukin-1 family</span> Group of cytokines playing a key role in the regulation of immune and inflammatory responses

The Interleukin-1 family is a group of 11 cytokines that plays a central role in the regulation of immune and inflammatory responses to infections or sterile insults.

Neuroinflammation is inflammation of the nervous tissue. It may be initiated in response to a variety of cues, including infection, traumatic brain injury, toxic metabolites, or autoimmunity. In the central nervous system (CNS), including the brain and spinal cord, microglia are the resident innate immune cells that are activated in response to these cues. The CNS is typically an immunologically privileged site because peripheral immune cells are generally blocked by the blood–brain barrier (BBB), a specialized structure composed of astrocytes and endothelial cells. However, circulating peripheral immune cells may surpass a compromised BBB and encounter neurons and glial cells expressing major histocompatibility complex molecules, perpetuating the immune response. Although the response is initiated to protect the central nervous system from the infectious agent, the effect may be toxic and widespread inflammation as well as further migration of leukocytes through the blood–brain barrier may occur.

<span class="mw-page-title-main">Raz Yirmiya</span>

Raz Yirmiya is an Israeli behavioral neuroscientist and director of the Laboratory for Psychoneuroimmunology at the Hebrew University of Jerusalem in Israel. He is best known for providing the first experimental evidence for the role of immune system activation in depression, for discovering that disturbances in brain microglia cells underlie some forms of depression, and for elucidating the involvement of inflammatory cytokines in regulation of cognitive and emotional processes.

Immuno-psychiatry, according to Pariante, is a discipline that studies the connection between the brain and the immune system. It differs from psychoneuroimmunology by postulating that behaviors and emotions are governed by peripheral immune mechanisms. Depression, for instance, is seen as malfunctioning of the immune system.

Major depression is often associated or correlated with immune function dysregulation, and the two are thought to share similar physiological pathways and risk factors. Primarily seen through increased inflammation, this relationship is bidirectional with depression often resulting in increased immune response and illness resulting in prolonged sadness and lack of activity. This association is seen both long-term and short-term, with the presence of one often being accompanied by the other and both inflammation and depression often being co-morbid with other conditions.

<span class="mw-page-title-main">Keith W. Kelley</span> American immunophysiologist, researcher and academic

Keith W. Kelley is an American immunophysiologist, researcher and academic. He is Professor Emeritus of Immunophysiology at the University of Illinois. Kelley was chosen as the second Editor-In-Chief of Brain, Behavior, and Immunity in 2003 and served in that capacity for 15 years. It is now considered “the best immunology journal in the neurosciences.” In 1994, he was elected as Secretary-Treasurer of the newly-formed Psychoneuroimmunology Research Society (PNIRS) and served as its President from 1999-2000. He retired from the University of Illinois in 2011, but continues to serve as a global leader in psychoneuroimmunology, creating PNIRSAsia-Pacific and PNIRSIbero-America. These scientific networks were formed to organize meetings that promote dialogue among Eastern and Western scientists engaged in psychoneuroimmunology research, as well as with those in South/Central America. As of 2023, over 30 of these meetings have been organized, mostly in China, but throughout the whole of Asia-Oceania.

<span class="mw-page-title-main">Interleukin 17F</span>

Interleukin 17F (IL-17F) is signaling protein that is in human is encoded by the IL17F gene and is considered a pro-inflammatory cytokine. This protein belongs to the interleukin 17 family and is mainly produced by the T helper 17 cells after their stimulation with interleukin 23. However, IL-17F can be also produced by a wide range of cell types, including innate immune cells and epithelial cells.

References

  1. 1 2 3 4 5 6 Hart, BL (1988). "Biological basis of the behavior of sick animals". Neuroscience and Biobehavioral Reviews. 12 (2): 123–137. doi:10.1016/S0149-7634(88)80004-6. PMID   3050629. S2CID   17797005.
  2. ↑ Kent, S.; Bluthe, R. M.; Dantzer, R.; Hardwick, A. J.; Kelley, K. W.; Rothwell, N. J.; Vannice, J. L. (1992). "Different receptor mechanisms mediate the pyrogenic and behavioral effects of interleukin 1". Proceedings of the National Academy of Sciences of the United States of America. 89 (19): 9117–9120. Bibcode:1992PNAS...89.9117K. doi: 10.1073/pnas.89.19.9117 . PMC   50076 . PMID   1409612.
  3. ↑ Exton, M. S. (1997). "Infection-Induced Anorexia: Active Host Defence Strategy". Appetite. 29 (3): 369–383. doi:10.1006/appe.1997.0116. PMID   9468766. S2CID   10465902.
  4. ↑ Murray, M. J.; Murray, A. B. (1979). "Anorexia of infection as a mechanism of host defense". The American Journal of Clinical Nutrition. 32 (3): 593–596. doi:10.1093/ajcn/32.3.593. PMID   283688.
  5. ↑ Mullington, J.; Korth, C.; Hermann, D. M.; Orth, A.; Galanos, C.; Holsboer, F.; Pollmächer, T. (2000). "Dose-dependent effects of endotoxin on human sleep". American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 278 (4): R947–R955. doi:10.1152/ajpregu.2000.278.4.r947. PMID   10749783. S2CID   10272455.
  6. ↑ Maier, SF; Wiertelak, EP; Martin, D; Watkins, LR (1993). "Interleukin-1 mediates the behavioral hyperalgesia produced by lithium chloride and endotoxin". Brain Research. 623 (2): 321–324. doi:10.1016/0006-8993(93)91446-Y. PMID   8221116. S2CID   40529634.
  7. ↑ Dantzer R, Kelley KW (February 2007). "Twenty years of research on cytokine-induced sickness behavior". Brain Behav. Immun. 21 (2): 153–160. doi:10.1016/j.bbi.2006.09.006. PMC   1850954 . PMID   17088043.
  8. 1 2 Kelley, KW; Bluthé, RM; Dantzer, R; Zhou, JH; Shen, WH; Johnson, RW; Broussard, SR (2003). "Cytokine-induced sickness behavior". Brain, Behavior, and Immunity. 17 (Suppl 1): S112–S118. doi:10.1016/S0889-1591(02)00077-6. PMID   12615196. S2CID   25400611.
  9. ↑ Johnson, R. W. (2002). "The concept of sickness behavior: A brief chronological account of four key discoveries". Veterinary Immunology and Immunopathology. 87 (3–4): 443–450. doi:10.1016/S0165-2427(02)00069-7. PMID   12072271.
  10. ↑ Dantzer, Robert (May 2009). "Cytokine, Sickness Behavior, and Depression". Immunology and Allergy Clinics of North America. 29 (2): 247–264. doi:10.1016/j.iac.2009.02.002. PMC   2740752 . PMID   19389580 . Retrieved 23 February 2015.
  11. ↑ Holmes, J. E.; Miller, N. E. (1963). "Effects of Bacterial Endotoxin on Water Intake, Food Intake, and Body Temperature in the Albino Rat". The Journal of Experimental Medicine. 118 (4): 649–658. doi:10.1084/jem.118.4.649. PMC   2137667 . PMID   14067912.
  12. ↑ Miller, N. (1964) "Some psychophysiological studies of motivation and of the behavioral effects of illness". Bull. Br. Psychol. Soc. 17: 1–20
  13. 1 2 Shakhar K, Shakhar G (Oct 2015). "Why Do We Feel Sick When Infected-Can Altruism Play a Role?". PLOS Biol. 13 (10): e1002276. doi: 10.1371/journal.pbio.1002276 . PMC   4608734 . PMID   26474156.
  14. 1 2 Steinkopf L (Aug 2015). "The Signaling Theory of Symptoms: An Evolutionary Explanation of the Placebo Effect". Evolutionary Psychology. 13 (3): 100. doi: 10.1177/1474704915600559 . PMC   10480909 . PMID   37924177.
  15. ↑ Kluger, M. J.; Rothenburg, B. A. (1979). "Fever and reduced iron: Their interaction as a host defense response to bacterial infection". Science. 203 (4378): 374–376. Bibcode:1979Sci...203..374K. doi:10.1126/science.760197. PMID   760197.
  16. ↑ Weinberg, E. D. (1984). "Iron withholding: A defense against infection and neoplasia". Physiological Reviews. 64 (1): 65–102. doi:10.1152/physrev.1984.64.1.65. PMID   6420813.
  17. ↑ Konsman, JP; Parnet, P; Dantzer, R (March 2002). "Cytokine-induced sickness behaviour: mechanisms and implications". Trends in Neurosciences. 25 (3): 154–159. doi:10.1016/s0166-2236(00)02088-9. PMID   11852148. S2CID   29779184.
  18. ↑ Goehler, L. E.; Gaykema, R. P.; Nguyen, K. T.; Lee, J. E.; Tilders, F. J.; Maier, S. F.; Watkins, L. R. (1999). "Interleukin-1beta in immune cells of the abdominal vagus nerve: A link between the immune and nervous systems?". The Journal of Neuroscience. 19 (7): 2799–2806. doi: 10.1523/JNEUROSCI.19-07-02799.1999 . PMC   6786076 . PMID   10087091.
  19. ↑ Goehler, L. E.; Relton, J. K.; Dripps, D.; Kiechle, R.; Tartaglia, N.; Maier, S. F.; Watkins, L. R. (1997). "Vagal paraganglia bind biotinylated interleukin-1 receptor antagonist: A possible mechanism for immune-to-brain communication". Brain Research Bulletin. 43 (3): 357–364. doi:10.1016/s0361-9230(97)00020-8. PMID   9227848. S2CID   22591654.
  20. ↑ Konsman, J. P.; Kelley, K.; Dantzer, R. (1999). "Temporal and spatial relationships between lipopolysaccharide-induced expression of Fos, interleukin-1beta and inducible nitric oxide synthase in rat brain". Neuroscience. 89 (2): 535–548. doi:10.1016/s0306-4522(98)00368-6. PMID   10077334. S2CID   25173830.
  21. ↑ Banks, W. A.; Kastin, A. J.; Gutierrez, E. G. (1994). "Penetration of interleukin-6 across the murine blood-brain barrier". Neuroscience Letters. 179 (1–2): 53–56. doi:10.1016/0304-3940(94)90933-4. PMID   7845624. S2CID   22712577.
  22. ↑ Banks, W. A.; Ortiz, L.; Plotkin, S. R.; Kastin, A. J. (1991). "Human interleukin (IL) 1 alpha, murine IL-1 alpha and murine IL-1 beta are transported from blood to brain in the mouse by a shared saturable mechanism". The Journal of Pharmacology and Experimental Therapeutics. 259 (3): 988–996. PMID   1762091.
  23. ↑ Ban, E.; Haour, F.; Lenstra, R. (1992). "Brain interleukin 1 gene expression induced by peripheral lipopolysaccharide administration". Cytokine. 4 (1): 48–54. doi:10.1016/1043-4666(92)90036-Q. PMID   1535519.
  24. ↑ Van Dam, A. M.; Brouns, M.; Louisse, S.; Berkenbosch, F. (1992). "Appearance of interleukin-1 in macrophages and in ramified microglia in the brain of endotoxin-treated rats: A pathway for the induction of non-specific symptoms of sickness?". Brain Research. 588 (2): 291–296. doi:10.1016/0006-8993(92)91588-6. PMID   1393581. S2CID   35583973.
  25. ↑ Brydon, L.; Walker, C.; Wawrzyniak, A.; Whitehead, D.; Okamura, H.; Yajima, J.; Tsuda, A.; Steptoe, A. (2009). "Synergistic effects of psychological and immune stressors on inflammatory cytokine and sickness responses in humans". Brain, Behavior, and Immunity. 23 (2): 217–224. doi:10.1016/j.bbi.2008.09.007. PMC   2637301 . PMID   18835437.
  26. ↑ Exton, M. S.; Bull, D. F.; King, M. G. (1995). "Behavioral conditioning of lipopolysaccharide-induced anorexia". Physiology & Behavior. 57 (2): 401–405. doi:10.1016/0031-9384(94)00249-5. PMID   7716224. S2CID   41061406.
  27. ↑ Exton, M. S.; Bull, D. F.; King, M. G.; Husband, A. J. (1995). "Modification of body temperature and sleep state using behavioral conditioning". Physiology & Behavior. 57 (4): 723–729. doi:10.1016/0031-9384(94)00314-9. PMID   7777610. S2CID   927502.
  28. ↑ Yirmiya, R.; Weidenfeld, J.; Pollak, Y.; Morag, M.; Morag, A.; Avitsur, R.; Barak, O.; Reichenberg, A.; Cohen, E.; Shavit, Y.; Ovadia, H. (1999). "Cytokines, "Depression Due to a General Medical Condition," and Antidepressant Drugs". Cytokines, Stress, and Depression. Advances in Experimental Medicine and Biology. Vol. 461. pp. 283–316. doi:10.1007/978-0-585-37970-8_16. ISBN   978-0-306-46135-4. PMID   10442179.
  29. ↑ Dantzer, R.; O'Connor, J. C.; Freund, G. G.; Johnson, R. W.; Kelley, K. W. (2008). "From inflammation to sickness and depression: When the immune system subjugates the brain". Nature Reviews Neuroscience. 9 (1): 46–56. doi:10.1038/nrn2297. PMC   2919277 . PMID   18073775.
  30. ↑ Maes, M. (2008). "The cytokine hypothesis of depression: Inflammation, oxidative & nitrosative stress (IO&NS) and leaky gut as new targets for adjunctive treatments in depression". Neuro Endocrinology Letters. 29 (3): 287–291. PMID   18580840.
  31. ↑ Yirmiya, R. (1996). "Endotoxin produces a depressive-like episode in rats". Brain Research. 711 (1–2): 163–174. doi:10.1016/0006-8993(95)01415-2. PMID   8680860. S2CID   46133689.
  32. 1 2 Harrison NA, Brydon L, Walker C, Gray MA, Steptoe A, Critchley HD (September 2009). "Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity". Biol Psychiatry. 66 (5): 407–414. doi:10.1016/j.biopsych.2009.03.015. PMC   2885494 . PMID   19423079.
  33. ↑ Drevets WC, Savitz J, Trimble M (August 2008). "The subgenual anterior cingulate cortex in mood disorders". CNS Spectr. 13 (8): 663–681. doi:10.1017/s1092852900013754. PMC   2729429 . PMID   18704022. PDF:http://mbldownloads.com/0808CNS_BrainRegions.pdf
  34. ↑ Cleeland, C. S.; Bennett, G. J.; Dantzer, R.; Dougherty, P. M.; Dunn, A. J.; Meyers, C. A.; Miller, A. H.; Payne, R.; Reuben, J. M.; Wang, X. S.; Lee, B. N. (2003). "Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism?". Cancer. 97 (11): 2919–2925. doi:10.1002/cncr.11382. PMID   12767108. S2CID   23198802.
  35. ↑ Myers, J. S. (2008). "Proinflammatory Cytokines and Sickness Behavior: Implications for Depression and Cancer-Related Symptoms". Oncology Nursing Forum. 35 (5): 802–807. doi:10.1188/08.ONF.802-807. PMID   18765326.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.